Patients were assessable if eligible for the MA .27 trial , received some trial therapy , and had no disease recurrence at the end of a symptom assessment period ; 96 % of patients ( n = 7,306 patients ) were included at 6 months , and 96 % ( n = 7,246 ) were included at 12 months .